According to the organization, the well-being of oral health professionals who provide oral health care and educate future dental professionals is a top priority for ADEA, which believes that the oral health community must continue to set a positive example when it comes to vaccinations.
ADEA's statement comes in the wake of an Executive Order requiring COVID-19 vaccinations for federal employees.
Additionally, a Joint Statement issued by the American Public Health Association and more than four dozen other health care organizations calls for all health care and long-term care employers to require their employees to receive the COVID-19 vaccine.
The Centers for Disease Control and Prevention has more detail on the COVID-19 vaccines and their effectiveness in reducing transmission of the coronavirus.
The American Dental Education Association is The Voice of Dental Education.
Its mission is to lead and support the health professions community in preparing future-ready oral health professionals.
ADEA members include all 78 US and Canadian dental schools, more than 800 allied and advanced dental education programs, more than 50 corporations and approximately 18,000 individuals.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100